Author:
Wai Abraham Ka-chung,Lee Teddy Tai-loy,Chan Sunny Ching-long,Chan Crystal Ying,Yip Edmond Tsz-fung,Luk Luke Yik-fung,Ho Joshua Wing-kei,So Kevin Wang-leong,Tsui Omar Wai-kiu,Lam Man-lok,Lee Shi-yeow,Yamamoto Tafu,Tong Chak-kwan,Wong Man-sing,Wong Eliza Lai-yi,Rainer Timothy Hudson
Abstract
AbstractThis study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk COVID-19 patients during an Omicron outbreak. Two cohorts, Nirmatrelvir-Ritonavir versus control and Molnupiravir versus control, were constructed with inverse probability treatment weighting to balance baseline characteristics. Cox proportional hazards models evaluated the association of their use with all-cause mortality, respiratory mortality, and all-cause sepsis (a composite of circulatory shock, respiratory failure, acute liver injury, coagulopathy, and acute liver impairment). Patients recruited were hospitalized and diagnosed with the COVID-19 Omicron variant between February 22, 2022 and April 15, 2022, and followed up until May 15, 2022. The study included 17,704 patients. There were 4.67 and 22.7 total mortalities per 1000 person-days in the Nirmatrelvir-Ritonavir and control groups respectively before adjustment (weighted incidence rate ratio, − 18.1 [95% CI − 23.0 to − 13.2]; hazard ratio, 0.18 [95% CI, 0.11–0.29]). There were 6.64 and 25.9 total mortalities per 1000 person-days in the Molnupiravir and control groups respectively before adjustment (weighted incidence rate ratio per 1000 person-days, − 19.3 [95% CI − 22.6 to − 15.9]; hazard ratio, 0.23 [95% CI 0.18–0.30]). In all-cause sepsis, there were 13.7 and 35.4 organ dysfunction events per 1000 person-days in the Nirmatrelvir-Ritonavir and control groups respectively before adjustment (weighted incidence rate ratio per 1000 person-days, − 21.7 [95% CI − 26.3 to − 17.1]; hazard ratio, 0.44 [95% CI 0.38–0.52]). There were 23.7 and 40.8 organ dysfunction events in the Molnupiravir and control groups respectively before adjustment (weighted incidence ratio per 1000 person-days, − 17.1 [95% CI, − 20.6 to − 13.6]; hazard ratio, 0.63 [95% CI 0.58–0.69]). Among COVID-19 hospitalized patients, use of either Nirmatrelvir-Ritonavir or Molnupiravir compared with no antiviral use was associated with a significantly lower incidence of 28-days all-cause and respiratory mortality and sepsis.
Funder
The Tung’s Foundation
AIR@InnoHK of the Innovation and Technology Commission
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Organization. WH. Tracking SARS-CoV-2 variants (2022) [Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.
2. Organization. WH. WHO Coronavirus (COVID-19) Dashboard (2020) [Available from: https://covid19.who.int/?gclid=CjwKCAjwkYGVBhArEiwA4sZLuNN_QKvxWQaLdOHcSneX_tD8dY7l60_eeSUPV0jSIG85YmDh6AKMNxoC_fAQAvD_BwE.
3. Del Rio, C., Omer, S. B. & Malani, P. N. Winter of Omicron—The evolving COVID-19 pandemic. JAMA 327(4), 319–320 (2022).
4. Young, B., Fong, S. –W., Chang, Z. W., Tan, K. S., Rouers, A., Goh, Y. S., et al. Comparison of the clinical features, viral shedding and immune response in vaccine breakthrough infection by the Omicron and Delta variants (2022).
5. Sun, Y.-J. et al. Clinical features of fatalities in patients with COVID-19. Disaster Med. Public Health Prep. 15(2), e9–e11 (2021).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献